Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus epoetin alfa in ESA-naive transfusion-dependent lower-risk MDS
2017-003190-34Phase 3Unknown
- Sponsor
- Celgene Corporation
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Luspatercept with Epoetin alfa (2 arms). Status: unknown.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2017-003190-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003190-34.